Acquired resistance to EGFR TKIs is the main limitation to a long-lasting benefit of these targeted agents in patients with EGFR mutation-positive NSCLC [32], with the EGFR T790 M mutation being responsible for resistance in up to 60% of cases [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.